These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 26040420)

  • 21. Activating mutation in the catalytic domain of c-kit elicits hematopoietic transformation by receptor self-association not at the ligand-induced dimerization site.
    Tsujimura T; Hashimoto K; Kitayama H; Ikeda H; Sugahara H; Matsumura I; Kaisho T; Terada N; Kitamura Y; Kanakura Y
    Blood; 1999 Feb; 93(4):1319-29. PubMed ID: 9949175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
    Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
    Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
    [TBL] [Abstract][Full Text] [Related]  

  • 23. KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor.
    Kohl TM; Schnittger S; Ellwart JW; Hiddemann W; Spiekermann K
    Blood; 2005 Apr; 105(8):3319-21. PubMed ID: 15618474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early myeloid cells expressing c-KIT isoforms differ in signal transduction, survival and chemotactic responses to Stem Cell Factor.
    Young SM; Cambareri AC; Odell A; Geary SM; Ashman LK
    Cell Signal; 2007 Dec; 19(12):2572-81. PubMed ID: 17855052
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KIT D816V is dimerization-independent and activates downstream pathways frequently perturbed in mastocytosis.
    Rajan V; Prykhozhij SV; Pandey A; Cohen AM; Rainey JK; Berman JN
    Br J Haematol; 2023 Sep; 202(5):960-970. PubMed ID: 35245395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Casitas B-lineage lymphoma mutants activate AKT to induce transformation in cooperation with class III receptor tyrosine kinases.
    Polzer H; Janke H; Schmid D; Hiddemann W; Spiekermann K
    Exp Hematol; 2013 Mar; 41(3):271-80.e4. PubMed ID: 23127761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SRC-like adaptor protein 2 (SLAP2) is a negative regulator of KIT-D816V-mediated oncogenic transformation.
    Rupar K; Moharram SA; Kazi JU; Rönnstrand L
    Sci Rep; 2018 Apr; 8(1):6405. PubMed ID: 29686302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Src-like-adaptor protein (SLAP) differentially regulates normal and oncogenic c-Kit signaling.
    Kazi JU; Agarwal S; Sun J; Bracco E; Rönnstrand L
    J Cell Sci; 2014 Feb; 127(Pt 3):653-62. PubMed ID: 24284075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing β-catenin signaling.
    Jin B; Ding K; Pan J
    Mol Cancer Ther; 2014 May; 13(5):1217-30. PubMed ID: 24552773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.
    Pan J; Quintás-Cardama A; Kantarjian HM; Akin C; Manshouri T; Lamb P; Cortes JE; Tefferi A; Giles FJ; Verstovsek S
    Blood; 2007 Jan; 109(1):315-22. PubMed ID: 16912224
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of the MAP kinase pathway by c-Kit is PI-3 kinase dependent in hematopoietic progenitor/stem cell lines.
    Wandzioch E; Edling CE; Palmer RH; Carlsson L; Hallberg B
    Blood; 2004 Jul; 104(1):51-7. PubMed ID: 14996702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers.
    Roberts KG; Smith AM; McDougall F; Carpenter H; Horan M; Neviani P; Powell JA; Thomas D; Guthridge MA; Perrotti D; Sim AT; Ashman LK; Verrills NM
    Cancer Res; 2010 Jul; 70(13):5438-47. PubMed ID: 20551067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance to c-KIT kinase inhibitors conferred by V654A mutation.
    Roberts KG; Odell AF; Byrnes EM; Baleato RM; Griffith R; Lyons AB; Ashman LK
    Mol Cancer Ther; 2007 Mar; 6(3):1159-66. PubMed ID: 17363509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit.
    Corbin AS; Demehri S; Griswold IJ; Wang Y; Metcalf CA; Sundaramoorthi R; Shakespeare WC; Snodgrass J; Wardwell S; Dalgarno D; Iuliucci J; Sawyer TK; Heinrich MC; Druker BJ; Deininger MW
    Blood; 2005 Jul; 106(1):227-34. PubMed ID: 15746079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential stimulation of c-Kit mutants by membrane-bound and soluble Steel Factor correlates with leukemic potential.
    Gommerman JL; Sittaro D; Klebasz NZ; Williams DA; Berger SA
    Blood; 2000 Dec; 96(12):3734-42. PubMed ID: 11090054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Kit-activating mutation D816V enhances stem cell factor--dependent chemotaxis.
    Taylor ML; Dastych J; Sehgal D; Sundstrom M; Nilsson G; Akin C; Mage RG; Metcalfe DD
    Blood; 2001 Aug; 98(4):1195-9. PubMed ID: 11493470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant.
    Shivakrupa R; Bernstein A; Watring N; Linnekin D
    Cancer Res; 2003 Aug; 63(15):4412-9. PubMed ID: 12907613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 8p12 stem cell myeloproliferative disorder: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathways.
    Guasch G; Ollendorff V; Borg JP; Birnbaum D; Pébusque MJ
    Mol Cell Biol; 2001 Dec; 21(23):8129-42. PubMed ID: 11689702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade.
    Harir N; Boudot C; Friedbichler K; Sonneck K; Kondo R; Martin-Lannerée S; Kenner L; Kerenyi M; Yahiaoui S; Gouilleux-Gruart V; Gondry J; Bénit L; Dusanter-Fourt I; Lassoued K; Valent P; Moriggl R; Gouilleux F
    Blood; 2008 Sep; 112(6):2463-73. PubMed ID: 18579792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PIK3CA-mediated PI3-kinase signalling is essential for HPV-induced transformation in vitro.
    Henken FE; Banerjee NS; Snijders PJ; Meijer CJ; De-Castro Arce J; Rösl F; Broker TR; Chow LT; Steenbergen RD
    Mol Cancer; 2011 Jun; 10():71. PubMed ID: 21663621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.